Clinical trials: Chronic Lymphocytic Leukaemia (CLL), open to volunteers
Chronic Lymphocytic Leukaemia (CLL), Small Lymphocytic Lymphoma (SLL)
Phase I/II Open-label Study Evaluating The Safety And Efficacy of Concomitant Administration of Anti-CD19 CAR T-cell Therapy and Lenalidomide in Refractory/Relapsed Chronic Lymphocytic Leukemia Patients.
This is a Phase I/II interventional, open-label treatment study designed to evaluate the safety and efficacy of concomitant therapy with anti-CD19 CAR T-cells and Lenalidomide in adult patients with relapsed/refractory chronic…
- Trial name
- VTB-CLL002 (NCT06762431)
- Testing
- Lenalidomide, Obinutuzumab Injection [Gazyva]
- Where
- Belarus
- Volunteers
- 24 people
- Sponsor
- Vitebsk Regional Clinical Cancer Centre
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Study on the Diagnosis and Management of CLL in Italy by GIMEMA
retrospective and prospective multicenter observational clinical and biological data collection from all patients with newly diagnosed CLL, SLL or MBL.
- Conditions
- Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, MBL-CLL - Monoclonal B-Cell Lymphocytosis Chronic Lymphocytic Leukaemia-Type
- Trial name
- NCT04867915
- Where
- 24 sites in Italy
- Volunteers
- 12,500 people
- Sponsor
- Gruppo Italiano Malattie EMatologiche dell'Adulto
Chronic Lymphocytic Leukaemia (CLL), Multiple Myeloma (MM)
Developing a Patient-Reported Outcome (PRO) Screening Measure for Infections and Measuring Quality of Life in Hematological Patients With Secondary Immunodeficiency (SID) Across the Treatment Trajectory - The PRO SID Project
The goal of this observational study is to improve the treatment of hematological patients with secondary immunodeficiency (SID) by developing a patient-reported outcome (PRO) instrument to detect clinically diagnosed infections.
- Conditions
- Chronic Lymphocytic Leukaemia (CLL), Multiple Myeloma (MM), Secondary Immunodeficiency (SID)
- Trial name
- PRO-SID (NCT06821880)
- Where
- 5 sites in Austria, Germany
- Volunteers
- 120 people
- Sponsor
- Medical University Innsbruck